Antitumor Efficacy of a Thrombospondin 1 Mimetic CovX-Body
Open Access
- 1 August 2011
- journal article
- Published by Elsevier BV in Translational Oncology
- Vol. 4 (4), 249-257
- https://doi.org/10.1593/tlo.11136
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Evolution of Potent and Stable Placental-Growth-Factor-1-Targeting CovX-Bodies from Phage Display Peptide DiscoveryJournal of Medicinal Chemistry, 2011
- SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancerAnnals Of Oncology, 2010
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Endogenous angiogenesis inhibitorsAPMIS, 2004
- Regulation of angiogenesis by the hemostatic systemFrontiers in Bioscience-Landmark, 2003
- Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growthJournal of Cellular and Molecular Medicine, 2002
- Fibrinolysis and angiogenesis in wound healingThe Journal of Pathology, 1991
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971